

Edgar Filing: VIREXX MEDICAL CORP - Form 6-K

VIREXX MEDICAL CORP  
Form 6-K  
November 28, 2005

FORM 6-K

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

For the month ended

November 2005

Commission File  
Number  
1-32608

VIREXX MEDICAL CORP.  
(Translation of registrant's name  
into English)

8223 Roper Road NW, Edmonton,  
Alberta, Canada T6E 6S4  
(Address of principal executive  
offices)

Indicate by check mark whether the registrant files or will file  
annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-  
K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-  
K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information  
contained in this Form, the registrant is also thereby furnishing  
the information to the Commission pursuant to Rule 12g3-2(b)  
under the Securities Exchange Act of 1934.

Yes ..... No ..X..

If "Yes" is marked, indicate below the file number assigned to  
the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

Edgar Filing: VIREXX MEDICAL CORP - Form 6-K

EXHIBIT LIST

Exhibit	Description
99.1 News Release	(ViRexx Announces Third Quarter Results)
99.2	(Financial Statements for the Quarter ended September 30, 2005)
99.3 News Release	(ViRexx Announces Marc Canton to Present at Technology Finance Conference 2005)
99.4 News Release	(ViRexx Announces Positive Interim Results for OcclusinT 50 Injection)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VIREXX MEDICAL CORP.

Date: November 23, 2005

By /s/ Marc Canton

:

Marc Canton, President